Maynard Ryan D 4

What Happened
Maynard Ryan D, chief financial officer of Foghorn Therapeutics, received a grant (transaction code A) of options covering 400,000 shares on February 23, 2026. The option’s stated exercise price is $5.75 per share, which multiplies to $2,300,000 (400,000 × $5.75) in nominal exercise value. The filing classifies this as a derivative award (an option grant), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-23; Form 4 filed: 2026-02-24 (appears timely).
• Award: 400,000 option shares; exercise price: $5.75; dollar figure listed: $2,300,000 (400,000 × $5.75).
• Transaction code: A (award/grant, derivative).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote (vesting): The option vests 25% on Feb 23, 2027, then 6.25% of the underlying shares on the first day of each calendar quarter thereafter until fully vested. (Footnote F1)
• Note: The $2.3M number reflects exercise price × shares, not the option’s fair-market or grant value.

Context
This was a compensation equity grant (option) that vests over time; there is no indication the options were exercised or shares sold. Such grants are common for executive retention and align pay with future performance; they do not directly signal immediate buying or selling of stock.